BRKR logo

Bruker Corporation Stock Price

NasdaqGS:BRKR Community·US$7.8b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 33 Fair Values set on narratives written by author

BRKR Share Price Performance

US$53.41
22.63 (73.52%)
US$59.75
Fair Value
US$53.41
22.63 (73.52%)
10.6% undervalued intrinsic discount
US$59.75
Fair Value
Price US$53.41
AnalystConsensusTarget US$59.75
AnalystHighTarget US$63.51
AnalystLowTarget US$42.30

BRKR Community Narratives

·
Fair Value US$59.75 10.6% undervalued intrinsic discount

BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience

0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
·
Fair Value US$63.51 15.9% undervalued intrinsic discount

Growing Global Health R&D Investment Will Boost Diagnostic Demand

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$42.3 26.3% overvalued intrinsic discount

Falling Funding Will Depress Revenues But Cost Cuts Help Margins

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$42.3
26.3% overvalued intrinsic discount
Profit Margin
10.02%
Future PE
21.13x
Price in 2029
US$53.83
US$59.75
10.6% undervalued intrinsic discount
Profit Margin
8.1%
Future PE
35.27x
Price in 2029
US$75.34
US$63.51
15.9% undervalued intrinsic discount
Revenue
3.99% p.a.
Profit Margin
11.61%
Future PE
27.24x
Price in 2028
US$80.52

Trending Discussion

No trending discussion available.

Updated Narratives

BRKR logo

BRKR: Premium Multiple Will Face Earnings Risk After Recent Guidance Miss

Fair Value: US$42.3 26.3% overvalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
BRKR logo

BRKR: Infection Detection Expansion Will Meet Rich Tools Sector Expectations

Fair Value: US$59.75 10.6% undervalued intrinsic discount
15 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
BRKR logo

Growing Global Health R&D Investment Will Boost Diagnostic Demand

Fair Value: US$63.51 15.9% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with moderate growth potential.

1 Risk
3 Rewards

Bruker Corporation Key Details

US$3.5b

Revenue

US$1.8b

Cost of Revenue

US$1.7b

Gross Profit

US$1.8b

Other Expenses

-US$106.9m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.70
48.48%
-3.05%
75.4%
View Full Analysis

About BRKR

Founded
1960
Employees
11085
CEO
Frank Laukien
WebsiteView website
www.bruker.com

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.

Recent BRKR News & Updates

Narrative Update Aug 07

BRKR: Premium Multiple Will Face Earnings Risk After Recent Guidance Miss

The updated analyst price target for Bruker moves from an implied fair value of about $35.00 to approximately $42.30 as analysts balance slightly higher assumed profit margins and P/E expectations, more cautious revenue growth forecasts, and an unchanged mix of Neutral, Hold, Buy, Overweight and Peer Perform ratings across recent research. Analyst Commentary Recent Street research on Bruker shows a mix of enthusiasm and caution, with several firms adjusting price targets and ratings as they reassess valuation, growth assumptions, and execution risks ahead of earnings updates.
Seeking Alpha Aug 05

Weak Growth In Its Primary Market Continues To Weigh Heavily On Bruker Shares

Summary Bruker faces ongoing headwinds from weak academic/government funding that has compressed growth despite strong semiconductor and energy research markets. Q2 delivered strong order growth and margin improvement, but revenue missed expectations and near-term guidance is soft, raising execution risk for FY targets. BRKR's high exposure to academic/government end markets remains a structural challenge, but growth in biopharma, diagnostics, and semiconductor segments offers long-term upside. Valuation appears modestly attractive with potential 30%+ upside, yet tepid organic growth and guidance uncertainty temper immediate buy conviction. Read the full article on Seeking Alpha

Recent updates

No updates